This article is more than 5 years old. Information may no longer be current.
FDA approves additional indication for Vistakon contact lens
JACKSONVILLE, Fla. — The U.S. Food and Drug Administration has approved Vistakon's Acuvue Oasys with Hydraclear Plus contact lens for additional therapeutic uses, the company announced in a press release.
Oasys contact lenses are now approved for use as bandage contact lenses for certain acute and chronic ocular conditions and can be worn continuously for up to 6 nights and 7 days. They can also provide vision correction during healing, according to the release.
The approval was based on a retrospective study of clinical data for 43 patients fitted with Oasys lenses for therapeutic applications. The study showed that the lens is effective in reducing corneal exposure, managing pain, protecting the barrier and preventing recurrent damage. Also, researchers observed no safety issues associated with therapeutic use of the lens, the release said.
Vistakon is a division of Johnson & Johnson Vision Care.